Volume 18, Issue 7, Pages (July 2010)

Slides:



Advertisements
Similar presentations
Volume 18, Issue 7, Pages (July 2010)
Advertisements

AAV-1–mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells by Federico Mingozzi, Janneke.
Volume 20, Issue 2, Pages (February 2012)
Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer by George Buchlis, Gregory M. Podsakoff,
Volume 19, Issue 12, Pages (December 2011)
Volume 49, Issue 1, Pages (January 2006)
Autoantibodies in Scurfy Mice and IPEX Patients Recognize Keratin 14
Maintenance of HCV-specific T-cell responses in antibody-deficient patients a decade after early therapy by Nasser Semmo, Michaela Lucas, George Krashias,
A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia by Anja Ehrhardt, Hui.
Volume 15, Issue 2, Pages (February 2007)
Volume 19, Issue 3, Pages (March 2011)
Volume 22, Issue 1, Pages (January 2014)
Volume 15, Issue 9, Pages (September 2007)
Cytomegalovirus-specific T cells are primed early after cord blood transplant but fail to control virus in vivo by Suzanne M. McGoldrick, Marie E. Bleakley,
Combined CD4+ Donor Lymphocyte Infusion and Low-Dose Recombinant IL-2 Expand FOXP3+ Regulatory T Cells following Allogeneic Hematopoietic Stem Cell Transplantation 
Juan Liu, Erin Harberts, Antonella Tammaro, Nicholas Girardi, Renata B
Volume 19, Issue 2, Pages (February 2011)
Volume 22, Issue 2, Pages (February 2014)
Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of.
Volume 19, Issue 8, Pages (August 2011)
Factor IX variants improve gene therapy efficacy for hemophilia B
Enhanced Factor VIII Heavy Chain for Gene Therapy of Hemophilia A
Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1.
Molecular Therapy - Methods & Clinical Development
Volume 4, Issue 6, Pages (December 2001)
Volume 22, Issue 5, Pages (May 2014)
Volume 23, Issue 3, Pages (March 2015)
Volume 25, Issue 6, Pages (June 2017)
Volume 15, Issue 2, Pages (February 2007)
Volume 19, Issue 3, Pages (March 2011)
Volume 22, Issue 3, Pages (March 2014)
Volume 23, Issue 12, Pages (December 2015)
Volume 20, Issue 2, Pages (February 2012)
Volume 19, Issue 11, Pages (November 2011)
Volume 18, Issue 6, Pages (June 2010)
Volume 15, Issue 9, Pages (September 2007)
Safety and efficacy of high-dose adeno-associated virus 9 encoding sarcoplasmic reticulum Ca2+ adenosine triphosphatase delivered by molecular cardiac.
Volume 23, Issue 10, Pages (October 2015)
Volume 16, Issue 12, Pages (December 2008)
Volume 19, Issue 2, Pages (February 2011)
Volume 18, Issue 2, Pages (February 2010)
Molecular Therapy - Methods & Clinical Development
Suppression of Murine Colitis and its Associated Cancer by Carcinoembryonic Antigen- Specific Regulatory T Cells  Dan Blat, Ehud Zigmond, Zoya Alteber,
Volume 25, Issue 6, Pages (June 2017)
Volume 3, Issue 5, Pages (May 2001)
Volume 18, Issue 1, Pages (January 2010)
Volume 147, Issue 4, Pages e8 (October 2014)
Volume 18, Issue 1, Pages (January 2010)
Volume 23, Issue 1, Pages (January 2015)
Volume 12, Issue 5, Pages (November 2005)
Andrew T Miller, Heather M Wilcox, Zhongbin Lai, Leslie J Berg 
Modular Three-component Delivery System Facilitates HLA Class I Antigen Presentation and CD8+ T-cell Activation Against Tumors  Benjamin J Umlauf, Chin-Ying.
Volume 18, Issue 9, Pages (September 2010)
Volume 19, Issue 6, Pages (June 2011)
Volume 17, Issue 2, Pages (February 2009)
Volume 22, Issue 2, Pages (February 2014)
Identification of mouse AAV capsid-specific CD8+ T cell epitopes
Volume 24, Issue 1, Pages (January 2016)
Volume 19, Issue 7, Pages (July 2011)
Volume 19, Issue 6, Pages (June 2011)
Volume 17, Issue 1, Pages (January 2009)
Volume 22, Issue 3, Pages (March 2014)
Volume 18, Issue 12, Pages (December 2010)
Volume 18, Issue 6, Pages (June 2010)
Volume 18, Issue 6, Pages (June 2010)
Volume 24, Issue 1, Pages (January 2016)
Interleukin-17A Promotes IgE Production in Human B Cells
Volume 19, Issue 5, Pages (May 2011)
Volume 16, Issue 4, Pages (April 2008)
Volume 16, Issue 4, Pages (April 2008)
Presentation transcript:

Volume 18, Issue 7, Pages 1318-1329 (July 2010) Safety of AAV Factor IX Peripheral Transvenular Gene Delivery to Muscle in Hemophilia B Dogs  Virginia Haurigot, Federico Mingozzi, George Buchlis, Daniel J Hui, Yifeng Chen, Etiena Basner-Tschakarjan, Valder R Arruda, Antoneta Radu, Helen G Franck, J Fraser Wright, Shangzhen Zhou, Hansell H Stedman, Dwight A Bellinger, Timothy C Nichols, Katherine A High  Molecular Therapy  Volume 18, Issue 7, Pages 1318-1329 (July 2010) DOI: 10.1038/mt.2010.73 Copyright © 2010 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 Humoral responses to capsid proteins after ATVRX or intramuscular (i.m.) vector delivery. Anti-AAV-2 capsid (a) IgG1 and (b) IgG2 subclass antibody titer measured by enzyme-linked immunosorbent assay; values are represented as average (n = 2 per time point) ± SD; animals received AAV-2 under immunosuppression (IS) by ATVRX at a dose of 1 × 1012 vg/kg (group A), 3 × 1012 vg/kg (group B), 8 × 1012 vg/kg (group C) or without IS at a dose of 3 × 1012 vg/kg either by ATVRX (group D) or i.m. (group E); x axis, time in days. ATVRX, afferent transvenular retrograde extravasation. Molecular Therapy 2010 18, 1318-1329DOI: (10.1038/mt.2010.73) Copyright © 2010 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 Time course of IL-10 ELISpot responses to canine FIX (cFIX) in dogs receiving AAV-2-cFIX vectors by ATVRX. Secretion of IL-10 from PBMCs after stimulation with peptides spanning the cFIX sequence organized in 19 pools. Samples were collected and analyzed at baseline, during IS and after IS discontinuation. Responses were considered positive when the number of spot-forming units (SFU) per million PBMCs were >50 and at least threefold higher than the media control (Med). All test conditions were assayed in triplicate. (a) Group A (1 × 1012 vg/kg with IS); (b) Group B (3 × 1012 vg/kg with IS); (c) Group C (8.5 × 1012 vg/kg with IS); (d) Group D (3 × 1012 vg/kg without IS). Baseline sample for J62 was not available; a sample obtained 1 week after vector delivery was analyzed instead. ATVRX, afferent transvenular retrograde extravasation; IL, interleukin; IS, immunosuppression; PBMC, peripheral blood mononuclear cell. Molecular Therapy 2010 18, 1318-1329DOI: (10.1038/mt.2010.73) Copyright © 2010 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 Time course of IL-10 ELISpot responses to canine FIX (cFIX) in dogs receiving AAV-2-cFIX vectors by ATVRX. Secretion of IL-10 from PBMCs after stimulation with peptides spanning the cFIX sequence organized in 19 pools. Samples were collected and analyzed at baseline, during IS and after IS discontinuation. Responses were considered positive when the number of spot-forming units (SFU) per million PBMCs were >50 and at least threefold higher than the media control (Med). All test conditions were assayed in triplicate. (a) Group A (1 × 1012 vg/kg with IS); (b) Group B (3 × 1012 vg/kg with IS); (c) Group C (8.5 × 1012 vg/kg with IS); (d) Group D (3 × 1012 vg/kg without IS). Baseline sample for J62 was not available; a sample obtained 1 week after vector delivery was analyzed instead. ATVRX, afferent transvenular retrograde extravasation; IL, interleukin; IS, immunosuppression; PBMC, peripheral blood mononuclear cell. Molecular Therapy 2010 18, 1318-1329DOI: (10.1038/mt.2010.73) Copyright © 2010 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 3 Analysis of canine FIX (cFIX) peptide pools which showed reactivity in the IL-10 ELISpots. (a) A peptide library of 89 peptides spanning the sequence of cFIX was organized into a matrix in which each peptide was represented in two orthogonal pools. Highlighted in grey are the pools that scored positive in most of the dogs analyzed. Positivity in two orthogonal pools identified a single stimulatory peptide, peptide 68. Peptide 68 amino acid sequence is indicated. (b) Peptides contained in pool 4 were rearranged into a smaller orthogonal matrix, allowing the identification of another reactive peptide that spanned the Chapel Hill mutation (peptide 84). *Chapel Hill mutation (glycin→glutamic acid) within peptide 84. (c) IL-10 secretion detected by ELISpot in PBMCs obtained form H24 (group C, ATVRX, 8.5 × 1012 vg/kg with IS) stimulated with the matrix represented in b. ELISpot, enzyme-linked immunosorbent assay; IL, interleukin; PBMC, peripheral blood mononuclear cell. Molecular Therapy 2010 18, 1318-1329DOI: (10.1038/mt.2010.73) Copyright © 2010 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 4 Expansion of CD4+IL-10+FoxP3+ T-cells in response to canine FIX (cFIX) antigens in dogs receiving an AAV-2-cFIX vector via ATVRX. (a) Top: ELISpot assay for IL-10 secretion after stimulation with purified canine FIX protein. Bottom: western blot analysis of cFIX protein in liver lysates from normal and HB dogs. (b) Staining for CD4+IL-10+FoxP3+ T-cells after in vitro restimulation with either cFIX protein (red line), peptide 68 from cFIX (blue line), or cFIX irrelevant pool (gray shaded area). Left panels, histogram plots showing IL-10 intracellular staining on CD4+ T-cells; right panels, FoxP3 staining on cells gated on CD4+IL-10+ T-cells. Cells were gated on lymphocytes, CD4+CD8−. ATVRX, afferent transvenular retrograde extravasation; AAV, adeno-associated virus; ELISpot, enzyme-linked immunosorbent spot; HB, hemophilia B; IL, interleukin. Molecular Therapy 2010 18, 1318-1329DOI: (10.1038/mt.2010.73) Copyright © 2010 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 5 Follow-up of cytokine profile in dogs receiving AAV vectors via ATVRX. Markers of innate and adaptive immune responses were analyzed simultaneously with a multiplex luminex-based assay in samples corresponding to baseline and days 1, 3, 21, and 60 postvector infusion by ATVRX. For each cytokine, the magnitude of the increase over baseline levels is color-coded. AAV, adeno-associated virus; ATVRX, afferent transvenular retrograde extravasation. Molecular Therapy 2010 18, 1318-1329DOI: (10.1038/mt.2010.73) Copyright © 2010 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 6 Biodistribution of vector genomes following ATVRX delivery of an AAV-2-cFIX vector. Quantitative PCR analysis of vector gene copy numbers/diploid genome in DNA samples extracted from different tissues 6 months postvector delivery by ATVRX. Results are shown as mean ± SD, n = 2. AAV, adeno-associated virus; ATVRX, afferent transvenular retrograde extravasation; cFIX, canine FIX. Molecular Therapy 2010 18, 1318-1329DOI: (10.1038/mt.2010.73) Copyright © 2010 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 7 Histology of muscle biopsies in dogs receiving AAV vectors by ATVRX or i.m. Hematoxylin and eosin staining of muscle biopsies obtained from the ATVRX dogs 6 months after gene transfer: (a) I07 and (b) H48, AAV-2, 3 × 1012 vg/kg with IS; (c) M25, AAV-2, 8.5 × 1012 vg/kg with IS; or (d) M13, AAV-6, 3 × 1012 vg/kg with IS. (e) Hematoxylin and eosin staining on muscle from dog M14, AAV-2, 3 × 1012 vg/kg, i.m. without IS. Asterisk denotes target limb. Black arrows indicate central nuclei, evidence of muscle regeneration. Images were all taken at a ×200 magnification. AAV, adeno-assocaited virus; ATVRX, afferent transvenular retrograde extravasation; G, gastrocnemius muscle; i.m., intramuscular; IS, immunosuppression; ST, semi-tendinosus muscle; VL, vastus lateralis muscle. Molecular Therapy 2010 18, 1318-1329DOI: (10.1038/mt.2010.73) Copyright © 2010 The American Society of Gene & Cell Therapy Terms and Conditions